Breast Health

SLOs:

• Outline the key stages of embryonic breast development

• Explain hormonal influences on pubertal breast development

• Describe breast tissue changes from adulthood through senescence

• Describe and explain how hormonal fluctuations at different life stages influence structural and functional changes in breast tissue

• Explain the preparation of breast tissue for lactation

• Develop management plans for common lactation-related conditions

General Instructions:

In this activity, you will demonstrate your understanding of breast physiology through the development of an educational resource and critical peer review.

Step 1: Research and Preparation

•  First, review the slide sets on "Breast Development" and "Reproductive Cycle Changes." These will provide you with foundational knowledge about embryonic development, pubertal changes, and reproductive cycle influences on breast tissue.

•  Then read the articles "Hormonal Regulation of Mammary Development and Milk Production" and "Breast Changes Throughout the Lifespan: A Comprehensive Review."

•  You may also wish to review additional resources on breast physiology and lactation management for a more comprehensive understanding.

Step 2: Create an Educational Resource

Develop an educational resource (800-1000 words) designed for healthcare professionals that addresses the following:

1. Create a comprehensive timeline of breast development and physiological changes from embryonic stage through senescence, highlighting key hormonal fluctuations, and specific structural and functional tissue changes (e.g., ductal proliferation, lobular development, stromal changes).

2. Explain the physiological preparation of breast tissue for lactation, including cellular changes and hormonal regulation.

3. Design a decision-making algorithm for the assessment and management of one   common lactation-related condition (e.g., engorgement, mastitis, insufficient milk production), including evidence-based interventions.

4. Critically discuss how knowledge of normal breast physiology can inform clinical assessment and management of breast-related complaints across different life stages.
   

Your educational resource should be evidence-based, clinically relevant, and organized in a manner that facilitates learning and application in clinical practice. Ensure it is visually appealing. You can choose to create a PowerPoint, poster or blog post. 

Step 3: Share

To share your work, click on the "Add a new discussion topic" button under this post and copy/paste your complete Google Document content into the "Message" box. Make sure to reference others' intellectual property when necessary. All references should follow 7th Edition APA formatting. For further instructions, see the resource on the Himmelfarb Health Sciences Library: APA citation resource (N.B.: references are excluded from word counts).

SLOs:

• Differentiate between physiologic and pathologic nipple discharge and galactorrhea

• List red flag features of nipple discharge that suggest malignancy

• Describe a structured diagnostic approach to evaluating patients with nipple discharge and galactorrhea

• Create a management plan for cyclic mastalgia

• Diagnose lactational vs. non-lactational mastitis

• Implement appropriate antibiotic and supportive therapies for mastitis

• Differentiate fibroadenoma from other benign masses

• Evaluate and manage breast asymmetry

• Demonstrate proper technique for clinical breast examination with appropriate documentation

General Instructions:

In this activity, you will demonstrate your understanding of benign breast disorders through case analysis and development of evidence-based management plans.

Step 1: Select and Reflect

•  First, review the slide sets on "Nipple Discharge and Galactorrhea," "Breast Pain and Infections," and "Breast Masses and Structural Abnormalities." These will provide you with foundational knowledge about various benign breast conditions.

•  Then read the articles "Clinical Management of Benign Breast Disorders" and "Evidence-Based Approaches to Benign Breast Complaints."

•  You may also wish to review current clinical practice guidelines for the management of benign breast disorders from organizations such as the American College of Obstetricians and Gynecologists (ACOG) or the National Comprehensive Cancer Network (NCCN).

Step 2: Case Analysis and Management Plan

Based on your readings and research, analyze the following case and develop a comprehensive management plan (800-1000 words):

Case Scenario A:
A 32-year-old woman presents with a 3-month history of bilateral breast pain that worsens in the week before her menstrual period. She also reports intermittent clear nipple discharge from her right breast that occurs spontaneously. She recently noticed a mobile, firm, well-circumscribed mass in her left breast that is mildly tender to palpation.She also mentions she has noticed her breasts appear unequal in size over the past year. She has no personal or family history of breast cancer. She has had two pregnancies resulting in two live births and breastfed both children for approximately 6 months each. Her last menstrual period was 2 weeks ago, and she reports regular 28-day cycles.

Case Scenario B:

A 28-year-old woman who is six weeks postpartum and currently breastfeeding presents with unilateral breast swelling, localized erythema and warmth, increased pain, and a fever of 38.5°C  (101.3°F). She reports reduced drainage from the affected breast over the past 24 hours.She is exclusively breastfeeding and reports the baby has been feeding well. Upon examination, the right breast shows erythema in the upper outer quadrant with a tender, indurated area.

Your response should include:

1. Provide a differential diagnosis for each of the patient’s main concerns. 

• For Case A, you must differentiate physiologic from pathologic causes of the patient’s nipple discharge and differentiate fibroadenoma from other benign breast masses when addressing the palpable lesion. 

• For Case B, identify the differential diagnosis for lactational versus non-lactational mastitis and explain potential causes of breast asymmetry. You must justify each diagnosis with reference to the case details and relevant clinical features.

2. Describe a structured diagnostic workup for one of these 2 patients. This should include the additional history you would obtain, the components of the physical examination you would perform, and the imaging or laboratory studies you would pursue. As part of your physical examination description, you must demonstrate proper clinical breast examination documentation by describing the findings using clock-face notation, breast quadrants, and the measured distance of findings from the nipple, along with the characteristics of any palpable abnormalities (size, shape, consistency, mobility, skin changes).

3. For your chosen patient, develop an evidence-based management plan for the most likely diagnoses including pharmacologic and non-pharmacologic interventions. You should reference current clinical guidelines where appropriate. If choosing Case B, your management plan must include specific antibiotic selection, dosing, duration, and supportive therapies for mastitis treatment, explaining your rationale for the chosen approach.

4. For your chosen patient, discuss the red flag features that would alter your management approach. Identify findings that would raise concern for malignancy or complicated infection and explain how these findings would change your diagnostic or therapeutic plan.

5. For your chosen patient, draft 1 patient-centered education point that you would address. Your discussion should include guidance on symptom expectations, self-monitoring, breastfeeding recommendations when relevant, supportive strategies, and instructions for when to seek urgent follow-up care.

Step 3: Share

To share your work, click on the "Add a new discussion topic" button under this post and paste your work into the "Message" box. Make sure to reference others' intellectual property when necessary. All references should follow 7th Edition APA formatting. For further instructions, see the resource on the Himmelfarb Health Sciences Library: APA citation resource (N.B.: references are excluded from word counts).

SLOs:

• Counsel patients on modifiable risk factors

• Develop tailored screening plans for patients from populations experiencing disproportionate disease burden due to social determinants of health and structural inequities.

• Demonstrate proficiency with risk assessment tools (Gail, Tyrer-Cuzick, etc.)

• Develop personalized risk reduction plans

• Identify appropriate candidates for SERMs and aromatase inhibitors

• Counsel patients on risk/benefit of prophylactic surgery

• Determine appropriate candidates for breast MRI and supplemental screening

• Create individualized screening plans for high-risk patients

• Refer appropriate patients for genetic counseling based on updated criteria

General Instructions:

In this activity, you will demonstrate your understanding of breast cancer risk assessment and risk reduction strategies through the development of personalized risk management plans and peer evaluation.

Step 1: Research and Preparation

•  First, review the slide sets on "Breast Cancer Risk Factors," "Risk Reduction Strategies," and "Screening in High-Risk Populations." These will provide you with foundational knowledge about risk assessment and management.

•  Then read the articles "Current Approaches to Breast Cancer Risk Assessment" and "Evidence-Based Risk Reduction Strategies."

•  Familiarize yourself with at least two breast cancer risk assessment tools (e.g., Gail Model, Tyrer-Cuzick, Breast Cancer Surveillance Consortium Risk Calculator).

•  Review the current NCCN guidelines for breast cancer risk reduction and screening for high-risk individuals.

Step 2: Case Analysis and Risk Management Plans

Develop risk assessment and management plans (800-1000 words total) for TWO of the following case scenarios:

Case 1: A 42-year-old African American woman with no personal history of breast cancer. Her mother was diagnosed with breast cancer at age 58, and she has one sister who is breast cancer-free. She began menstruating at age 11, had her first child at age 32, and has never used hormone replacement therapy. She has a BMI of 31 and drinks 5-7 alcoholic beverages per week. She has never had a breast biopsy.

Case 2: A 35-year-old Hispanic woman whose maternal grandmother and maternal aunt were diagnosed with breast cancer at ages 45 and 50, respectively. She has no personal history of contraceptives for 15 years. She has a BMI of 24 and exercises regularly. She had a breast biopsy at age 30 that showed atypical ductal hyperplasia.

Case 3: A 55-year-old Caucasian woman who tested positive for a BRCA1 mutation. She has no personal history of breast or ovarian cancer. Her mother and sister both had breast cancer in their 40s. She began menstruating at age 12, had two children before age 30, and went through menopause at age 52. She has a BMI of 27 and is currently taking medication for hypertension.

For each of your 2 selected cases, your management plan should include:

1. A quantitative risk assessment using at least two validated tools, with justification for tool selection, comparison of outputs, and discussion of limitations and uncertainty in calculated risk.
   

2. An analysis of modifiable and non-modifiable risk factors, including explanation of how you would counsel this patient about modifiable risk reduction strategies. Integrate relevant population-level data on breast cancer incidence and outcomes while critically examining how social determinants of health influence risk and care for patients from marginalized communities."
   

3. A personalized risk reduction plan that incorporates patient-specific lifestyle modifications, chemoprevention strategies, and consideration of prophylactic surgery when appropriate. For chemoprevention, determine candidacy for SERMs or aromatase inhibitors and justify your recommendation with specific criteria.
   

4. A tailored screening plan with justification for the recommended modalities and intervals, including the evidence-based criteria used to determine eligibility for breast MRI or other supplemental screening.

5. Genetic counseling and testing recommendations based on updated NCCN criteria, including an explanation of which criteria the patient meets and how these influence management decisions.
   

6. One patient-centered counseling point, such as discussion of risks and benefits of preventive strategies, addressing patient concerns, clarifying misconceptions, and incorporating patient preferences into shared decision-making.

Step 3: Share

To share your work, click on the "Add a new discussion topic" button under this post and paste your work into the "Message" box. Make sure to reference others' intellectual property when necessary. All references should follow 7th Edition APA formatting. For further instructions, see the resource on the Himmelfarb Health Sciences Library: APA citation resource (N.B.: references are excluded from word counts).

SLOs:

• Differentiate between dominant and recessive inheritance

• Explain variable penetrance in BRCA mutations

• Recognize clinical features of hereditary breast cancer syndromes including PALB2, ATM, and CHEK2

• Select appropriate patients for genetic testing based on updated NCCN criteria

• Describe different genetic testing methodologies including VUS interpretation

• Develop management plans based on genetic findings

General Instructions:

In this activity, you will demonstrate your understanding of genetic principles in breast cancer risk assessment and management through the development of educational materials and peer evaluation.

Step 1: Research and Preparation

•  First, review the slide sets on "Principles of Cancer Genetics" and "Genetic Testing and Counseling." These will provide you with foundational knowledge about inheritance patterns, gene penetrance, and genetic testing methodologies.

•  Then read the articles "Hereditary Breast Cancer: Beyond BRCA" and "Clinical Management of Patients with Variants of Uncertain Significance."

•  Review the current NCCN guidelines for genetic/familial high-risk assessment for breast, ovarian, and pancreatic cancer.

•  You may also wish to review additional resources on cancer genetics and genetic testing for a more comprehensive understanding.

Step 2: Develop Educational Materials

Develop 2 educational materials (800-1000 words) for healthcare professionals that address the following:

Your responses must demonstrate clinical reasoning and application of genetic principles, not just summary of content.

1. Create a guide to hereditary breast cancer syndromes that includes the following:
   

• Define and differentiate between Autosomal dominant inheritance and Autosomal recessive inheritance. Explain why BRCA-related breast cancer follows dominant inheritance

• Include a sample three-generation pedigree demonstrating autosomal dominant inheritance in a breast cancer family with annotations showing:

1. Multiple affected individuals across generations

2. ~50% transmission pattern

3. Unaffected carriers (demonstrating incomplete penetrance)

• Explain how inheritance pattern informs genetic counseling (50% risk for first-degree relatives) and cascade testing strategy

• Include a comparison table of at least five hereditary breast cancer syndromes (including BRCA1/2, PALB2, ATM, and CHEK2), their inheritance patterns, estimated cancer risks, associated clinical features, and key evidence-based surveillance recommendations

• Explain variable penetrance and expressivity with specific examples related to breast cancer genes

• A discussion of gene-environment interactions in hereditary breast cancer

• Introduce risk-reducing intervention options with their efficacy and limitations and cascade testing recommendations for family members.

2. Develop a clinical decision algorithm for genetic testing referral and interpretation that includes:
   

• Outline the current NCCN criteria for genetic testing referral with specific attention to updates in the most recent guidelines

• Describe the following genetic testing technologies:

1. Next-generation sequencing (NGS): What it detects (point mutations, small indels), advantages (multi-gene panels, cost-effective), limitations (may miss large deletions/duplications)

2. Deletion/duplication analysis (MLPA or aCGH): What it detects (large rearrangements), why needed (~5-10% of BRCA mutations are large deletions missed by sequencing alone)

3. Sanger sequencing: When used (confirmation, known familial variants)

• Explain the following test selection approaches

1. Single-gene testing: When appropriate (known familial variant, specific syndrome suspicion)

2. Multi-gene panel testing: Advantages (comprehensive, identifies unexpected mutations), disadvantages (higher VUS rate)

3. Panel composition: Which genes to include based on clinical presentation

• A structured framework for interpreting and managing variants of uncertain significance (VUS)

Your educational materials should be evidence-based, clinically relevant, and organized in a manner that facilitates learning and application in clinical practice. Include visual elements (tables, algorithms, or decision trees) to enhance understanding.

Step 3: Share

To share your work, click on the "Add a new discussion topic" button under this post and paste your work into the "Message" box. Make sure to reference others' intellectual property when necessary. All references should follow 7th Edition APA formatting. For further instructions, see the resource on the Himmelfarb Health Sciences Library: APA citation resource (N.B.: references are excluded from word counts).

SLOs:

• Order appropriate diagnostic imaging studies

• Recognize suspicious findings on mammography, ultrasound, and MRI

• Apply BIRADS categories to clinical decision-making and follow-up planning

• Select appropriate biopsy technique based on lesion characteristics

• Interpret comprehensive breast pathology reports

• Explain the significance of ER, PR, HER2, and Ki-67 status in treatment planning

General Instructions:

In this activity, you will demonstrate your understanding of breast cancer diagnosis through analysis of imaging findings, biopsy selection, and pathology interpretation.

Step 1: Select and Reflect

•  First, review the slide sets on "Diagnostic Imaging" and "Tissue Diagnosis." These will provide you with foundational knowledge about imaging modalities, BIRADS classification, biopsy techniques, and pathology interpretation.

• Then read the articles "Current Approaches to Breast Cancer Diagnosis" and "Molecular Subtypes of Breast Cancer: Clinical Implications."

•  Review the ACR BI-RADS Atlas (5th edition) for mammography, ultrasound, and MRI.

•  You may also wish to review additional resources on breast imaging and pathology for a more comprehensive understanding.

Step 2: Case Analysis and Response

Based on your readings and research, analyze the following case scenarios and compose a 900-1100 word response:

Case Scenario- Part 1:Initial Presentation:

A 56-year-old woman with no personal history of breast cancer presents with a BI-RADS 0 screening mammogram showing a new 1.2 cm irregular density with indistinct margins in the upper outer quadrant of the right breast. She has a sister diagnosed with breast cancer at age 60, underwent menopause at age 52, and has a BMI of 28 with no significant breast symptoms. 

1. Diagnostic Imaging Algorithm and Ordering (200-250 Words)

1. Immediate Next Steps (100-120 words)

Develop your initial imaging workup by addressing the following considerations:

• What specific imaging study or studies would you order immediately for this patient? When ordering diagnostic mammography, specify which views you would include, such as spot compression views, magnification views, or additional projections, and explain your rationale for each selection.

• Explain why diagnostic mammography rather than repeat screening mammography is the appropriate next step for a BI-RADS 0 classification. What is the primary goal you hope to achieve with diagnostic mammography in this clinical scenario? 

• Determine whether ultrasound should be ordered at this point in the workup. If you decide ultrasound is indicated, specify the timing—should it be performed on the same day as the diagnostic mammogram, or should you wait to review the mammogram results first? 

• Discuss the specific indications for targeted ultrasound when evaluating a mammographic abnormality.

• Explain what additional diagnostic information ultrasound can provide beyond what mammography reveals about the lesion.

2.  Additional Imaging Considerations (80-100 words)

Evaluate whether there are any indications for breast MRI at this initial stage of the diagnostic workup. In your analysis, consider multiple factors including the patient's age, her family history of breast cancer, the imaging characteristics of the lesion, and her breast density. Discuss when MRI is indicated in the diagnostic setting as opposed to the screening setting. If you determine that MRI is not indicated at this time, describe the specific circumstances or findings that would prompt you to order MRI later in this patient's diagnostic evaluation.

Case Scenario - Part 2: Imaging Results

Following your imaging recommendations, the patient undergoes diagnostic mammography showing a 1.2 cm irregular mass with spiculated margins and associated pleomorphic microcalcifications in a clustered distribution within heterogeneously dense breast tissue (BI-RADS Density Category C). Targeted ultrasound reveals an irregular, hypoechoic mass measuring 1.3 cm at the 2 o'clock position, 4 cm from the nipple, with taller-than-wide orientation, angular spiculated margins, and posterior acoustic shadowing. No internal vascularity is seen on color Doppler, and no associated lymphadenopathy is identified.The radiologist is preparing the final report and needs to assign a BI-RADS category.

2. Recognition And Analysis Of Suspicious Imaging Findings (250-300 Words)

1. Mammographic Findings Analysis (80-100 words)

• Systematically identify and explain each suspicious feature visible on mammography. For the irregular mass with spiculated margins, describe what this morphology suggests about the nature of the lesion and explain specifically why this finding is concerning for malignancy. 

• Define what "pleomorphic" means in the context of microcalcifications and discuss why pleomorphic microcalcifications are considered suspicious. 

• Explain the significance of a clustered distribution pattern for microcalcifications. Compare these findings to how benign lesions would appear differently specifically, describe how a benign mass such as a fibroadenoma or benign calcifications such as vascular or coarse calcifications would present on mammography. 

• Comment on how heterogeneously dense breast tissue (Category C) affects the sensitivity of mammography for detecting breast lesions.

2.  Sonographic Findings Analysis (80-100 words)

• Systematically identify and explain each suspicious feature visible on ultrasound. Discuss the significance of finding an irregular, hypoechoic mass. 

• Explain why taller-than-wide orientation is concerning, specifically addressing how this violates normal tissue planes. 

• Describe what angular, spiculated margins suggest about the lesion's growth pattern and biological behavior. 

• Explain what causes posterior acoustic shadowing and what this finding indicates about the tissue characteristics of the mass.

•  Compare these suspicious features to how benign lesions would appear on ultrasound specifically, describe how a simple cyst or fibroadenoma would differ in their sonographic appearance from this lesion.

3.  BI-RADS Classification and Management (90-120 words)

• Based on the combined imaging findings from both mammography and ultrasound, assign the most appropriate BI-RADS category for this case and provide detailed justification for your classification choice. Consider the available options: BI-RADS 3 (Probably Benign), 4A (Low Suspicion for Malignancy), 4B (Moderate Suspicion for Malignancy), 4C (High Suspicion for Malignancy), or 5 (Highly Suggestive of Malignancy).

•  Explain the BI-RADS classification system by defining what each of these categories means, with particular focus on categories 3, 4A, 4B, 4C, and 5. 

• For your assigned category, state the estimated probability of malignancy and the recommended management according to BI-RADS guidelines.

•  Discuss how clinical management would differ if this lesion were classified as BI-RADS 3 versus 4C versus 5, highlighting the practical implications of each classification.

3.  Biopsy Technique Selection (200-250 Words)

Select and justify the most appropriate biopsy approach for this lesion.

Your response must address:

1. Biopsy Recommendation for This Case (80-100 words)

The imaging workup has identified a 1.3 cm sonographically visible mass with highly suspicious features requiring tissue diagnosis.

• Determine what biopsy technique you would recommend for this mass and provide comprehensive justification for your selection. Base your recommendation on multiple factors including the lesion's characteristics (size, location, and visibility on imaging), diagnostic accuracy requirements for this clinical scenario, patient-related factors, and cost-effectiveness considerations. 

2.  Comparative Analysis of Biopsy Techniques (120-150 words)

Create a comparative table listing all available biopsy techniques, analyzing fine needle aspiration (FNA), core needle biopsy (CNB), vacuum-assisted biopsy (VAB), and surgical excisional biopsy. 

• For each technique, mention the typical indications for use, the advantages that make it preferable in certain situations, the limitations that restrict its application, and the type and adequacy of samples obtained.

 After presenting this comparison, 

• Apply it specifically to this case by explaining why CNB or VAB is preferred over FNA for this lesion, considering the need for tissue architecture and biomarker testing. 

• Discuss why surgical biopsy should not be the first-line approach, despite being definitive, given that CNB or VAB is usually diagnostic and less invasive. 

• Comment on whether stereotactic biopsy would be appropriate if the lesion were not visible on ultrasound, considering scenarios where findings are only visible mammographically.

Case Scenario - Part 3: Biopsy Results

Pathology Report Summary

Specimen: Right breast core needle biopsy (upper outer quadrant, 2 o'clock position, 4 cm from nipple)

Diagnosis: Invasive ductal carcinoma, Grade 2

Key Findings :Tumor Characteristics: The biopsy reveals invasive ductal carcinoma (the most common breast cancer type) with Grade 2 histology, indicating moderate differentiation and intermediate aggressiveness. The Nottingham grading score is 6/9, with moderate scores across all three components: tubule formation, nuclear pleomorphism, and mitotic activity. Associated ductal carcinoma in situ (DCIS) with intermediate-grade features is present. No lymphovascular invasion was identified in the biopsy cores.

Biomarker Profile: The tumor is strongly hormone receptor-positive, with estrogen receptor expression in 90% of cells and progesterone receptor expression in 70% of cells, indicating excellent candidacy for endocrine therapy. HER2 status is equivocal (2+) by immunohistochemistry, requiring confirmatory FISH testing to determine eligibility for HER2-targeted therapy. The Ki-67 proliferation index of 25% suggests intermediate proliferative activity.

Molecular Subtype (Preliminary): Likely Luminal B subtype, pending final HER2 FISH results. This classification will determine whether HER2-targeted therapy should be added to the treatment regimen.

Recommended Next Steps: Surgical excision is recommended for definitive staging, assessment of tumor size and margins, evaluation of lymph node status, and treatment planning. The pathology findings are concordant with the suspicious imaging features, confirming appropriate tissue sampling.

4)  Comprehensive Pathology Report Interpretation (250-300 Words)

1.  Histopathologic Features Interpretation (100-120 words)

• Interpret the histologic type and grade of this tumor. 

• Explain what invasive ductal carcinoma, not otherwise specified (NOS), means and note its frequency among breast cancers (approximately 70-80% of cases). 

• For the Grade 2 designation with Nottingham score 6/9, explain the Nottingham grading system and how it combines tubule formation, nuclear pleomorphism, and mitotic count scores. 

• Discuss what Grade 2 means clinically in terms of differentiation and prognosis, and explain how histologic grade influences treatment decisions, particularly regarding the use of chemotherapy. 

• Address the significance of the associated DCIS component, including whether it affects surgical margins or extent of disease, and clarify whether the presence of DCIS changes the diagnosis from invasive cancer. 

• Discuss the finding that lymphovascular invasion (LVI) was not identified in this biopsy specimen, noting that it will be assessed in the surgical specimen and explaining why LVI is considered a risk factor for lymph node metastasis and distant recurrence.

2.  Biomarker Interpretation and Treatment Implications (150-180 words)

For each biomarker, briefly explain its significance and specific treatment and prognosis implications:

1. ER (90% positive): 

2. PR (70% positive).

3. HER2 (2+ equivocal):.

4. Ki-67 (25%): .

3. Molecular Subtyping and Clinical Implications (50-70 words)

• Define the four major molecular subtypes of breast cancer: Luminal A (ER/PR positive, HER2 negative, low Ki-67), Luminal B (ER positive with either HER2 positive or HER2 negative with high Ki-67), HER2-enriched (ER/PR negative, HER2 positive), and Triple-Negative/Basal-like (ER/PR/HER2 all negative). 

• For each subtype, describe the typical treatment approach and general prognosis. 

• Determine this tumor's likely molecular subtype based on the biomarker profile of ER positive (90%), PR positive (70%), HER2 equivocal (pending FISH), and Ki-67 25%. 

• Explain how the classification would differ depending on whether the HER2 FISH result is positive (Luminal B HER2-positive subtype) or negative (Luminal B HER2-negative subtype), and describe the corresponding treatment implications for each scenario.

• Discuss the role of multidisciplinary tumor boards in breast cancer diagnosis and initial treatment planning, including the specific contributions of each specialty (radiology, pathology, surgery, medical oncology, radiation oncology, genetics).

Step 3: Share

To share your work, click on the "Add a new discussion topic" button under this post and paste your work into the "Message" box. Make sure to reference others' intellectual property when necessary. All references should follow 7th Edition APA formatting. For further instructions, see the resource on the Himmelfarb Health Sciences Library: APA citation resource (N.B.: references are excluded from word counts).